Effectiveness, safety and predictors of response to vedolizumab as first- or second-line biological therapy in patients with ulcerative colitis: A real-world observational multicenter study.

被引：0

作者：

Ferreira, S. ^{[1
]}

Parra, R. Serafim ^{[2
]}

Sassaki, L. Yukie ^{[3
]}

Parente, J. M. Luz ^{[4
]}

de Mello, M. Kurtz ^{[5
]}

Chebli, L. Andrade ^{[6
]}

Luporini, R. L. ^{[7
]}

Alves Junior, A. J. Tiburcio ^{[8
]}

Nobrega, F. J. Firmino ^{[9
]}

da Silva, B. C. ^{[10
]}

Miranda, E. F. ^{[11
]}

Quaresma, A. Botelho ^{[12
]}

Nicollelli, G. Mattioli ^{[13
]}

Gasparini, R. Galhardi ^{[14
]}

Dutra, R. de Medeiros ^{[3
]}

da Silva, K. da Conceicao ^{[15
]}

Magro, D. Oliveira

Imbrizi, M. R. ^{[16
]}

Nagasako, C. Kibune ^{[17
]}

Feres, O. ^{[18
]}

Troncon, L. E. de Almeida ^{[19
]}

Kotze, P. G. ^{[20
]}

Chebli, J. M. Fonseca ^{[21
]}

机构：

[1] Hosp Clin Ribeirao Preto Med Sch, Med, Ribeirao Preto, Brazil

[2] Hosp Clin Ribeirao Preto Med Sch, Surg & Anat, Ribeirao Preto, SP, Brazil

[3] Sao Paulo State Univ UNESP, Med Sch, Internal Med, Botucatu, Brazil

[4] Univ Fed Piaui, Hlth Sci Ctr, Div Gastroenterol Med Course, Teresina, Brazil

[5] Univ Vale Itajai, Med, Itajai, Brazil

[6] Univ Fed Juiz de Fora, Div Gastroenterol, Med, Juiz De Fora, Brazil

[7] Fed Univ Sao Carlos UFSCar, Med, Sao Carlos, Brazil

[8] PUC Campinas Med Sch, Surg, Campinas, Brazil

[9] Univ Fed Paraiba, Lauro Wanderley Hosp, Gastroenterol, Joao Pessoa, Brazil

[10] Hosp Bahia, Gastroenterol, Salvador, Brazil

[11] Pontificia Univ Catolica Parana PUCPR, Surgey, Curitiba, Brazil

[12] Univ Oeste Santa Catarina UNOESC, Surg, Joacaba, Brazil

[13] Hosp Clin UFPR, Surg, Curitiba, Brazil

[14] Sete Specialized Med Ctr, Marilia, Brazil

[15] Hosp Univ Univ Fed Piaui, Med, Teresina, Brazil

[16] State Univ Campinas UNICAMP, Surg, Campinas, Brazil

[17] State Univ Campinas UNICAMP, Med, Campinas, Brazil

[18] Univ Sao Paulo, Ribeirao Preto Med Sch, Surg & Anat, Ribeirao Preto, Brazil

[19] Univ Sao Paulo, Ribeirao Preto Med Sch, Med, Ribeirao Preto, Brazil

[20] Pontificia Univ Catol Parana PUCPR, Hlth Sci Postgrad Program, Curitiba, Brazil

[21] Univ Fed Juiz de Fora, Div Gastroenterol, Med, Juiz De Fora, Brazil

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0856

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P0682

引用

页码：i1335 / i1336

页数：2

共 50 条

[21] Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
Calmejane, L.
Reenaers, C.
Amiot, A.
Nuzzo, A.
Vuitton, L.
Altwegg, R.
Guillo, L.
Wils, P.
Roblin, X.
Le Cosquer, G.
Simon, M.
Benezech, A.
Laharie, D.
Fumery, M.
Buisson, A.
Charkaoui, M.
Nancey, S.
Sabra, G.
Geyl, S.
Coffin, B.
Cavicchi, M.
Le Berre, C.
Goutorbe, F.
Bouguen, G.
Vidon, M.
Christmann, P. Y.
Kirchgesner, J.
Uzzan, M.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I699 - I699
[22] Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
Lair-Mehiri, L.
Stefanescu, C.
Vaysse, T.
Laharie, D.
Roblin, X.
Rosa, I.
Treton, X.
Abitbol, V.
Amiot, A.
Bouguen, G.
Dib, N.
Fumery, M.
Pariente, B.
Carbonnel, F.
Peryn-Biroulet, L.
Simon, M.
Viennot, S.
Bouhnik, Y.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S478 - S479
[23] Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population
Waddell, Tom
Pillai, Manon
Armitage, Kate
Graham, Donna M.
Moran, Michael
Dilleen, Maria
Holmes, Sinead
Sleszynska-Dopiera, Ewa
Hawkins, Robert
FUTURE ONCOLOGY, 2024, 20 (33) : 2547 - 2558
[24] Efficacy and safety of regorafenib alone or in combinations in the second-line setting for advanced hepatocellular carcinoma: A multicenter real-world study.
Zhang, Wei
Zhao, Yanrong
Ma, Guixiang
Zhang, Yu
Guo, Yuan
Chen, Zhong
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] Characteristics of Patients With Ulcerative Colitis Initiating Vedolizumab Therapy in Real-World Clinical Practice
Khalid, Javaria M.
Reynolds, Matthew
Alam, Naufi L.
Don, O'Hara
Smyth, Michael D. L.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S825 - S825
[26] Commentary on the real-world effectiveness of vedolizumab in therapy-experienced ulcerative colitis: A response to Azzam et al.
Alameel, Turki A.
Alhashim, Howra W.
SAUDI JOURNAL OF GASTROENTEROLOGY, 2025, 31 (02): : 100 - 101
[27] Systematic Literature Review of Real-World Effectiveness and Safety of Vedolizumab in Adult Ulcerative Colitis and Crohn's Disease Patients
Demuth, Dirk
Bovens, Sandra
Solaman, Angela
Curtis, Rebecca
O'Byrne, Sharon
Khalid, Javaria Mona
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S298 - S298
[28] Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis
Patel, Perseus V.
Zhang, Amy
Bhasuran, Balu
Ravindranath, Vignesh G.
Heyman, Melvin B.
Verstraete, Sofia G.
Butte, Atul J.
Rosen, Michael J.
Rudrapatna, Vivek A.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 78 (05): : 1126 - 1134
[29] Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study
Amiot, A.
Vered, A.
Filippi, J.
Cadiot, G.
Laharie, D.
Melanie, S.
Altwegg, R.
Bouhnik, Y.
Peyrin-biroulet, L.
Gilletta, C.
Roblin, X.
de Chambrun, G. Pineton
Vuitton, L.
Bourrier, A.
Nancey, S.
Gornet, J. M.
Nahon, S.
Bouguen, G.
Viennot, S.
Benjamin, P.
Fumery, M.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S579 - S579
[30] Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
Blomstrand, Hakon
Batra, Atul
Cheung, Winson Y.
Elander, Nils Oskar
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (09): : 787 - 799

← 1 2 3 4 5 →